Phase 2 findings (Jastreboff et al., 2023): At the highest dose studied, retatrutide produced a mean body weight reduction exceeding 17% at 24 weeks a result driven partly by appetite suppression and partly by increased energy expenditure linked to glucagon receptor agonism
The company also said it had conducted a retrospective review of its purchasing records and found no adverse events, but the agency said it was impossible to verify, as it had not received any documentation to support it, and raised concerns that the products it had already dispensed could not be traced in a recall
General optimization: Start conservative (10 units) and titrate to the minimum effective dose that produces your desired effects
Employers and patients might consider compounded versions during severe shortages or for significant cost savings, but these medications call for careful consideration
By the time symptoms appear, the fire has often been smoldering in the brain for decades
